Risk Benefit Analysis in Reference to use of LMWH in COVID-19.

Samajdar, Shambo Samrat; Sam, Priya Ann; Moitra, Saibal; Ray, Yogiraj; Pal, Jyotirmoy; Joshi, Shashank R; Tripathi, Santanu K

Samajdar, Shambo Samrat; Sam, Priya Ann; Moitra, Saibal; Ray, Yogiraj; Pal, Jyotirmoy; Joshi, Shashank R; Tripathi, Santanu K.

Afiliação

Samajdar SS; DM Resident in Clinical Pharmacology, School of Tropical Medicine, Kolkata.
Sam PA; Medical Advisor, Lupin Ltd., Mumbai.
Moitra S; Adjunct Professor and Senior Consultant, Department of Allergy and Immunology, Apollo Gleneagles Hospital, Kolkata.
Ray Y; Assistant Professor Tropical Medicine, School of Tropical Medicine, Kolkata and COVID CCU in charge ID and BG Hospital.
Pal J; Professor, Department of Internal Medicine, R G Kar Medical College and Hospital, Kolkata.
Joshi SR; Consultant Endocrinologist, Joshi Clinic, Mumbai.
Tripathi SK; Professor and Head, Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata.

J Assoc Physicians India ; 68(9): 52-61, 2020 Sep.

Article em En | MEDLINE | ID: mdl-32798346

Assuntos

Anticoagulantes/uso terapêutico; Betacoronavirus; Infecções por Coronavirus; Heparina de Baixo Peso Molecular/uso terapêutico; Pandemias; Pneumonia Viral; COVID-19; Humanos; Fatores de Risco; SARS-CoV-2

Buscar no Google

Imprimir

XML

PubMed Links

Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Heparina de Baixo Peso Molecular / Pandemias / Betacoronavirus / Anticoagulantes Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links